Qnovia will now initiate a trial to determine pharmacokinetics, safety and tolerability following self-administration of nicotine products. Read More
Tags :Qnovia
Despite the technology’s potential, the tobacco stigma remains a considerable hurdle. Read More
The new members are Neal Benowitz, Ian Fearon, Darla Kendzor and Nicole Nollen. Read More
QN-01 demonstrated a superior pharmacokinetic profile, according to Qnovia.Read More
Qnovia wants to increase smoking cessation rates with a disruptive inhaler technology.Read More
The firm will use the funds to develop a proof of concept and apply for FDA authorization.Read More
